In vivo effects of renal Npt2a inhibition

التفاصيل البيبلوغرافية
العنوان: In vivo effects of renal Npt2a inhibition
المؤلفون: Jessica A Dominguez Rieg, Timo Rieg, Linto Thomas, Jianxiang Xue
المصدر: Revista Cubana de Investigaciones Biomédicas, Vol 38, Iss 5 (2020)
بيانات النشر: Wiley, 2019.
سنة النشر: 2019
مصطلحات موضوعية: npt2a inhibitor, mice, urinary phosphate excretion, animal model, mice, lcsh:R5-920, In vivo, Chemistry, Genetics, Pharmacology, lcsh:Medicine (General), Molecular Biology, Biochemistry, Biotechnology
الوصف: Introduction: Hyperphosphatemia is common in patients with chronic kidney disease and associated with increased mortality. Oral phosphate binders and dietary phosphate restriction are the current management protocols for patients with hyperphosphatemia; however, their effectiveness is insufficient. In the kidney, the sodium-phosphate cotransporter Npt2a is responsible for bulk uptake of phosphate in the proximal tubule. Recently, an orally bioavailable selective Npt2a inhibitor (Npt2a-I, PF-06869206) has been described to reduce phosphate uptake in HEK cells transfected with mouse or rat Npt2a. So far, its physiological in vivo function has not been tested. Objective: To describe the in vivo effect of renal NPt2a inhibition in C57BL/6J mice Material and Methods: Based on in vitro IC 50 concentrations, we chose to study 30 mg/kg (oral gavage, 1% of body weight) in short-term (3 hours) metabolic cage experiments in C57BL/6J mice. Results: Compared to vehicle (n=14), bolus administration of Npt2a-I (n=12) caused significantly higher (~4-fold) urinary phosphate excretion (104±8 vs 27 ±6 µmol*min -1, P
تدمد: 1530-6860
0892-6638
DOI: 10.1096/fasebj.2019.33.1_supplement.751.2
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d56c61fd21f912a0c6dfe99fd0ccfa7
https://doi.org/10.1096/fasebj.2019.33.1_supplement.751.2
Rights: OPEN
رقم الانضمام: edsair.doi.dedup.....8d56c61fd21f912a0c6dfe99fd0ccfa7
قاعدة البيانات: OpenAIRE
الوصف
تدمد:15306860
08926638
DOI:10.1096/fasebj.2019.33.1_supplement.751.2